Conversion to sirolimus.
Ruiz
J C
JC
Servicio de Nefrología, Hospital Marqués de Valdecilla, Santander. ruizjc@humv.es
Alonso
A
A
Arias
M
M
Campistol
J M
JM
González Molina
M
M
González Posada
J M
JM
Grinyo
J M
JM
Morales
J M
JM
Oppenheimer
F
F
Sánchez Fructuoso
A
A
Sánchez-Plumed
J
J
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control; D004198:Disease Susceptibility; D004334:Drug Administration Schedule; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000517:prevention & control; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control; D016030:Kidney Transplantation; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D009369:Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D011183:Postoperative Complications / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D020123:Sirolimus